Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Arbutus Biopharma's share price for the quarter that ended in Mar. 2026 was $4.5. Arbutus Biopharma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 196.9 Mil. Therefore, Arbutus Biopharma's market cap for the quarter that ended in Mar. 2026 was $886.3 Mil.
Arbutus Biopharma's quarterly market cap
increased
from Sep. 2025 ($871.5 Mil) to Dec. 2025 ($926.1 Mil) but then
declined
from Dec. 2025 ($926.1 Mil) to Mar. 2026 ($886.3 Mil).
Arbutus Biopharma's annual market cap
increased
from Dec. 2023 ($424.7 Mil) to Dec. 2024 ($621.2 Mil) and
increased
from Dec. 2024 ($621.2 Mil) to Dec. 2025 ($926.1 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Arbutus Biopharma's Enterprise Value for Today is $759.8 Mil.
Arbutus Biopharma (NAS:ABUS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Arbutus Biopharma Market Cap Related Terms
Arbutus Biopharma Market Cap Historical Data
* Premium members only.
The historical data trend for Arbutus Biopharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Arbutus Biopharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arbutus Biopharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Arbutus Biopharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Arbutus Biopharma's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arbutus Biopharma (ABUS) has a Market Cap of $854.4 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Arbutus Biopharma and its competitors. According to the industry distribution chart, Arbutus Biopharma ranks #299 out of 1431 companies in the Biotechnology industry, placing it in the top 20.9%.
Is Arbutus Biopharma's Market Cap too high?
Arbutus Biopharma's current Market Cap is $854.4 Mil. The Biotechnology industry median Market Cap is 117.63. Arbutus Biopharma's value of $854.4 Mil is 626.4% above this industry median. Based on the distribution chart, Arbutus Biopharma ranks #299 out of 1431 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arbutus Biopharma has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arbutus Biopharma's Market Cap compare to SPRY and KURA?
According to the Biotechnology industry distribution chart, Arbutus Biopharma ranks #299 out of 1431 companies for Market Cap. This places Arbutus Biopharma in the top 21% of its industry — outperforming the majority of peers. The industry median Market Cap is 117.63. Arbutus Biopharma's value of $854.4 Mil is 626.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.63, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arbutus Biopharma's current Market Cap of $854.4 Mil is 626.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Arbutus Biopharma and its competitors. For the Biotechnology industry, the median Market Cap is 117.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arbutus Biopharma's current Market Cap is $854.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arbutus Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Arbutus Biopharma (ABUS) is currently considered Possible Value Trap. The stock's GF Value™ is $51.42, compared to a current price of $4.33 — trading 91.6% below its estimated fair value. The current Market Cap is $854.4 Mil and 626.4% above the Biotechnology industry median of 117.63. Arbutus Biopharma's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Arbutus Biopharma (ABUS), the current Market Cap is $854.4 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arbutus Biopharma (ABUS) Overvalued in 2026?
Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued.
The current stock price of $4.33 is trading 91.6% below its estimated GF Value™ of $51.42.
GuruFocus considers Arbutus Biopharma to be Possible Value Trap.
Key valuation signals for ABUS:
Market Cap: $854.4 Mil
GF Value™: $51.42 vs. price of $4.33 (91.6% below fair value)
Industry Position: 626.4% above the Biotechnology median (#299 of 1431)
No single metric tells the full story. See the ABUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
53GF Score
Get the complete analysis for ABUS
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABUS has been successfully added to your 
